Wachovia believes BioMarin Pharmaceutical’s (NASDAQ: BMRN) shares are oversold after yesterday’s conference call about the company's drug, Kuvan, which is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE